Clarity in action

We are determined to bring the full power of data to the collective fight against cancer.

Our Approach

Through our research and partnerships, we are helping to shape the real-world evidence industry and advance the field of oncology.
Our collaborations are leading industry to advance the treatment landscape, reimagine the drug development life cycle, and accelerate value-based care models.

Latest Blog Posts

Real-World Data and its Role in Addressing Cancer Health Disparities

Leveraging RWD to gain insight into cancer health disparities affecting underserved populations is key to ensuring equitable access, care, and outcomes for all patients.

Celebrating Black History Month by Supporting Equity in Clinical Trials

We work with large, de-identified data sets extracted and curated from the universe of electronic health records, claims systems, and myriad other sources. And yet, we are always brought back to the fact that amidst the data are the stories of people’s lives and their journeys of care.

COTA Expands Life Sciences Team By Bringing On Key Hire, Shariq Alavi

In our ongoing mission to bring clarity to cancer care, COTA is proud to share a new addition to our growing team — Shariq Alavi. He joins COTA as a new Vice President of Life Sciences.

Latest Podcasts

Our Research and Publications

Discover more about how our work with the FDA, industry and academia helps to ensure that everyone touched by cancer is given a clear path to the right care.

ASH 2020: Real-World Treatment Patterns and Outcomes of Patients with Functional High-Risk (Early Relapse) Multiple Myeloma

In collaboration with researchers from the University of Texas Southwestern Medical Center, this retrospective study uses RWD to explore treatment patterns and outcomes of functional high-risk multiple myeloma patients who relapse within 18 months of initial diagnosis.

Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study

In this retrospective observational cohort study involving 13 hospitals within the Hackensack Meridian Health network (NJ, USA), patients with COVID-19 requiring ICU support who received tocilizumab had reduced mortality. Results of ongoing randomized controlled trials are awaited.

ESMO IO 2019: Cost of Adverse Events (AEs) With Second-line (2L) Immuno-Oncology Agents (IO) and Chemotherapy (CHEMO) in Advanced Non-Small Cell Lung Cancer (aNSCLC) in the Real World

In collaboration with Bristol-Myers Squibb, COTA investigated the incidence and cost of adverse events among aNSCLC patients treated with 2L immuno-oncology agents as compared to 2L chemotherapy, finding lower cost among patients treated with IO.

An Exploratory Analysis of Real-World End Points for Assessing Outcomes Among Immunotherapy-Treated Patients With Advanced Non–Small-Cell Lung Cancer

COTA was one of six organizations to participate in a collaboration to explore the consistency of real-world endpoints across diverse datasets and the potential validity of RWD to support regulatory and payer decision making.

ASCO 2019: Rates of Genotyping for KRAS, NRAS, BRAF, Microsatellite Instability, and Mismatch Repair in Metastatic Colon Cancer Patients: Gaps and Implications.

In collaboration with Guardant Health, COTA investigated the molecular testing rates of patients with metastatic colon cancer and found that <25% of our cohort received guideline recommended genotyping.

ASCO 2019: Real-World Characterization of Advanced/Metastatic Non-Small Cell Lung Cancer Patients with Rapid Disease Progression

In collaboration with Eli Lilly, COTA characterized patients with non-small cell lung cancer whose disease progresses within <12 weeks of diagnosis, a notable poor prognosis cohort.

Interested in learning more about how we can transform cancer care together?